Abstract: A method for combining with a minimum isolation bandwidth includes: determining an insertion loss and an isolation between ports of a combiner; calculating a total isolation bandwidth of an isolation band in the combiner according to the insertion loss and the isolation between ports; determining guard bandwidths adjacent to the isolation band in combined systems, the combined systems being at least two communication systems combined by the combiner; and, calculating an actual isolation bandwidth of the combiner according to the guard bandwidths of the combined systems and the total isolation bandwidth.

Abstract: The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/US/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to rMuVIowa/US/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuV?SH) and/or incapable of expressing the V protein (rMuV?V).

Abstract: The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5V?C), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI?), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI?, rPIV5-CPI+, rPIV5-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-5443P, rPIV5-MDA7, rPIV5?SH-CPI?, or rPIV5?SH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.

Abstract: Antibodies that specifically bind to a Sonic Hedgehog (Shh) polypeptide, or an antigen binding fragment thereof, are provided. Also provided are methods of treating an individual for cancer using the Shh polypeptide antibodies. Methods of analyzing a tissue sample for cell-surface expression of a full-length Shh polypeptide are also provided.

Abstract: An information sharing method for a smart electricity meter, the smart electricity meter and an acquisition router are provided. Multiple Internet Protocol version 6 (IPv6) addresses are allocated to the smart electricity meter; the smart electricity meter specifies the corresponding IPv6 address according to a type of information to initiate a Transmission Control Protocol (TCP)/Internet Protocol (IP) connection to the acquisition router; and the acquisition router searches for routing IPv6 addresses with same rules as rules of the IPv6 address according to the IPv6 address, and sends the information to destination addresses specified by the information through the routing IPv6 addresses.

Abstract: A method and circuit for controlling or starting a U-shape single phase synchronous permanent magnetic motor (U-SPSPM motor) having a rotor and a stator and coupled to a single phase alternating current (AC) power source through a switch, including estimating back electromotive force (back-EMF) of the motor based on an observer model with inputs indicative of the measured signals, and triggering the switch to supply power to the motor based on the estimates of the back-EMF.

Abstract: A method and circuit for controlling or starting a U-shape single phase synchronous permanent magnetic motor (U-SPSPM motor) having a rotor and a stator and coupled to a single phase alternating current (AC) power source through a switch, including estimating back electromotive force (back-EMF) of the motor based on an observer model with inputs indicative of the measured signals, and triggering the switch to supply power to the motor based on the estimates of the back-EMF.

Abstract: Compositions, methods of use and methods of manufacture are provided for PIV5-based amplifying VLP (AVLP) that can deliver an expressible heterologous nucleotide sequence in target cells without producing progeny, and which demonstrate useful safety and therapeutic efficacy in multiple animal and human health applications, such as vaccination, gene therapy and cancer therapy.

Abstract: The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma.

Abstract: The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a GLI polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof.

Abstract: A method for combining with a minimum isolation bandwidth includes: determining an insertion loss and an isolation between ports of a combiner; calculating a total isolation bandwidth of an isolation band in the combiner according to the insertion loss and the isolation between ports; determining guard bandwidths adjacent to the isolation band in combined systems, the combined systems being at least two communication systems combined by the combiner; and, calculating an actual isolation bandwidth of the combiner according to the guard bandwidths of the combined systems and the total isolation bandwidth.

Abstract: The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5V?C), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI?), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI?, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-5443P, rPIV5-MDA7, rPIV5?SH-CPI?, or rPIV5?SH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.

Abstract: A method and circuit for controlling or starting a U-shape single phase synchronous permanent magnetic motor (U-SPSPM motor) having a rotor and a stator and coupled to a single phase alternating current (AC) power source through a switch, including estimating back electromotive force (back-EMF) of the motor based on an observer model with inputs indicative of the measured signals, and triggering the switch to supply power to the motor based on the estimates of the back-EMF.

Abstract: The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/US/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to rMuVIowa/US/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuV?SH) and/or incapable of expressing the V protein (rMuV?V).

Abstract: The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VAC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI?), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI?, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-S443P, rPIV5-MDA7, rPIV5ASH-CPI?, or rPIV5ASH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.

Abstract: A method for controlling a U-shape single phase synchronous permanent magnetic motor having a rotor and a stator and coupled to a single phase alternating current (AC) power source through a switch includes estimating back-electromotive force and the position of the rotor based on a voltage feedback signal, a current feedback signal, and a phase feedback signal indicative of a zero-crossing of the single phase AC power source. Once the speed and position of the rotor are determined, a controller can trigger a switch to supply power to the motor.

Abstract: Disclosed in the present invention are 4-(5-amino-6-hydroxybenzoxazol-2-yl)ammonium benzoate shown in formula (I) and the preparation method and use thereof. The preparation method comprises: fully reacting 4-(5-amino-6-hydroxybenzoxazol-2-yl)benzoic acid shown in formula (II) or 4-(5-amino-6-hydroxybenzoxazol-2-yl)carboxamide benzoate, as a raw material, with ammonia in an aqueous solvent, and directly heating the obtained reaction liquid to remove excess ammonia, so as to obtain 4-(5-amino-6-hydroxybenzoxazol-2-yl)ammonium benzoate. The mass of the 4-(5-amino-6-hydroxybenzoxazol-2-yl)ammonium benzoate (ABAA) prepared in the present invention can reach a polymer grade (where the purity is above 99.

Abstract: A method for controlling a U-shape single phase synchronous permanent magnetic motor having a rotor and a stator and coupled to a single phase alternating current (AC) power source through a switch includes estimating back-electromotive force and the position of the rotor based on a voltage feedback signal, a current feedback signal, and a phase feedback signal indicative of a zero-crossing of the single phase AC power source. Once the speed and position of the rotor are determined, a controller can trigger a switch to supply power to the motor.

Abstract: The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/us/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to MuVIowa/us/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuV?SH) and/or incapable of expressing the V protein (rMuV?V).

Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.